S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

November 30, 2007

Study Completion Date

June 30, 2011

Conditions
Lymphoma
Interventions
BIOLOGICAL

filgrastim

5 ug/kg

BIOLOGICAL

rituximab

375 mg/m\^2 on day 1 of cycles 1-6

DRUG

cyclophosphamide

300 mg/m\^2 on days 2-4 of cycles 1,3,5,7

DRUG

cytarabine

12 g/m\^2 over days 3-4 of cycles 2,4,6,8

DRUG

dexamethasone

40 mg on days 2-5 and 12-15 of cycles 1,3,5,7

DRUG

doxorubicin

16.6 mg/m\^2/day for days 5-7 of cycles 1,3,5,7

DRUG

leucovorin

170 mg over days 3-5 of cycles 2,4,6,8

DRUG

methotrexate

1000 mg/m\^2 over days 2-3 of cycles 2,4,6,8

DRUG

vincristine

1.4 mg/m\^2 on days 5 and 12 of cycles 1,3,5,7

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK

NCT00041132 - S0213 Chemotherapy Plus Rituximab in Treating Patients With Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter